BRPI0516152A - formulação farmacêutica que compreende microcápsulas de estatinas ressuspensas em éster alquìlicos de ácidos graxos poli-insaturados (pufa) - Google Patents
formulação farmacêutica que compreende microcápsulas de estatinas ressuspensas em éster alquìlicos de ácidos graxos poli-insaturados (pufa)Info
- Publication number
- BRPI0516152A BRPI0516152A BRPI0516152-5A BRPI0516152A BRPI0516152A BR PI0516152 A BRPI0516152 A BR PI0516152A BR PI0516152 A BRPI0516152 A BR PI0516152A BR PI0516152 A BRPI0516152 A BR PI0516152A
- Authority
- BR
- Brazil
- Prior art keywords
- pufa
- microcapsules
- pharmaceutical formulation
- fatty acid
- polyunsaturated fatty
- Prior art date
Links
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title abstract 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 239000003094 microcapsule Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 125000005907 alkyl ester group Chemical group 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
FORMULAçãO FARMACêUTICA QUE COMPREENDE MICROCáPSULAS DE ESTATINAS RESSUSPENSAS EM éSTER ALQUìLICOS DE áCIDOS GRAXOS POLI-INSATURADOS (PUFA). Formulação farmacêutica composta por uma suspensão que compreende um óleo com elevado conteúdo de Þsteres alquílicos de ácido graxo poli-insaturado (PUFA) e microcápsulas as quais compreendem pelo menos um polímero e uma estatina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200402492A ES2255426B1 (es) | 2004-10-19 | 2004-10-19 | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
PCT/ES2005/000542 WO2006045865A1 (es) | 2004-10-19 | 2005-10-13 | Formulación farmacéutica que comprende microcapsulas de estatinas suspendidas en ester alquílicos de ácidos grasos poliinsaturados (pufa) |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0516152A true BRPI0516152A (pt) | 2008-08-26 |
Family
ID=36227494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516152-5A BRPI0516152A (pt) | 2004-10-19 | 2005-10-13 | formulação farmacêutica que compreende microcápsulas de estatinas ressuspensas em éster alquìlicos de ácidos graxos poli-insaturados (pufa) |
Country Status (22)
Country | Link |
---|---|
US (1) | US20090196920A1 (pt) |
EP (1) | EP1803440B1 (pt) |
JP (1) | JP4976302B2 (pt) |
KR (1) | KR101413339B1 (pt) |
CN (2) | CN102727462A (pt) |
AT (1) | ATE469641T1 (pt) |
AU (1) | AU2005298587B2 (pt) |
BR (1) | BRPI0516152A (pt) |
CA (1) | CA2583756C (pt) |
CY (1) | CY1110751T1 (pt) |
DE (1) | DE602005021668D1 (pt) |
DK (1) | DK1803440T3 (pt) |
EA (1) | EA012371B1 (pt) |
ES (2) | ES2255426B1 (pt) |
IL (1) | IL182466A (pt) |
MX (1) | MX2007004655A (pt) |
NZ (1) | NZ554265A (pt) |
PL (1) | PL1803440T3 (pt) |
PT (1) | PT1803440E (pt) |
SI (1) | SI1803440T1 (pt) |
WO (1) | WO2006045865A1 (pt) |
ZA (1) | ZA200703509B (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0610344A2 (pt) | 2005-12-13 | 2016-11-29 | Teva Pharma | forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal |
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
AU2007245410A1 (en) | 2006-04-26 | 2007-11-08 | Rosemont Pharmaceuticals Ltd | Liquid oral compositions |
WO2008000731A2 (en) * | 2006-06-26 | 2008-01-03 | Valpharma S.A. | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids |
CN101484144A (zh) * | 2006-07-06 | 2009-07-15 | 特瓦特药工业有限公司 | 具有受控药物动力学的组合物 |
ITMI20072142A1 (it) | 2007-11-08 | 2009-05-09 | Yervant Zarmanian | Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3 |
GB0724735D0 (en) | 2007-12-19 | 2008-01-30 | Psynova Neurotech Ltd | Methods and biomarkers for diagnosing and monitoring psychotic disorders |
JP5421126B2 (ja) * | 2008-01-10 | 2014-02-19 | 武田薬品工業株式会社 | カプセル製剤 |
GB0818472D0 (en) * | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
ES2363964B1 (es) * | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
ES2363965B1 (es) * | 2009-11-20 | 2013-01-24 | Gp Pharm S.A. | Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados. |
ES2364011B1 (es) * | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
SG10201408508YA (en) | 2009-12-23 | 2015-02-27 | Defiante Farmacêutica S A | Combination composition useful for treating cardiovascular diseases |
CA2706270C (en) * | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
CA2706272C (en) | 2010-06-03 | 2020-05-05 | Accucaps Industries Limited | Multi phase soft gel capsules, apparatus and method thereof |
US8609138B2 (en) | 2010-06-30 | 2013-12-17 | Mochida Pharmaceutical Co., Ltd. | ω3 fatty acid compound preparation |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
KR101310710B1 (ko) * | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물 |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
KR101466617B1 (ko) * | 2011-11-17 | 2014-11-28 | 한미약품 주식회사 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
JP6173437B2 (ja) | 2012-05-07 | 2017-08-02 | オムセラ・ファーマシューティカルズ・インコーポレイテッド | スタチン及びω−3脂肪酸の組成物 |
WO2013176455A1 (ko) | 2012-05-22 | 2013-11-28 | 건일제약 주식회사 | 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물 |
CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
WO2014182003A1 (en) * | 2013-05-06 | 2014-11-13 | Hanmi Pharm. Co., Ltd. | Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof |
KR102240429B1 (ko) * | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
WO2015185240A1 (en) | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions containing simvastatin in omega-3 polyunsaturated fatty acids |
RU2614734C2 (ru) * | 2015-05-21 | 2017-03-28 | Татьяна Алексеевна Денисюк | Способ получения нанокапсул розувастатина в каррагинане |
KR101950907B1 (ko) | 2016-02-05 | 2019-02-21 | 한국유나이티드제약 주식회사 | 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제 |
US11904054B2 (en) * | 2018-01-19 | 2024-02-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
WO2022129002A1 (en) * | 2020-12-15 | 2022-06-23 | Dsm Ip Assets B.V. | Coarse dispersion comprising statin and vitamin e oil |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5312473B1 (pt) | 1971-05-24 | 1978-05-01 | ||
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5035896A (en) | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US5225202A (en) * | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
WO2000057859A1 (en) | 1999-03-31 | 2000-10-05 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
WO2000057918A2 (en) | 1999-03-31 | 2000-10-05 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
WO2002043659A2 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
WO2002100394A1 (en) * | 2001-06-12 | 2002-12-19 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
CA2456034A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
AU2003245313A1 (en) * | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
NZ539624A (en) * | 2002-09-27 | 2008-08-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
JP2006521366A (ja) * | 2003-03-28 | 2006-09-21 | シグモイド・バイオテクノロジーズ・リミテッド | シームレスマイクロカプセルを含む固形経口剤形 |
-
2004
- 2004-10-19 ES ES200402492A patent/ES2255426B1/es not_active Expired - Fee Related
-
2005
- 2005-10-13 PL PL05802903T patent/PL1803440T3/pl unknown
- 2005-10-13 AU AU2005298587A patent/AU2005298587B2/en not_active Ceased
- 2005-10-13 SI SI200531074T patent/SI1803440T1/sl unknown
- 2005-10-13 AT AT05802903T patent/ATE469641T1/de active
- 2005-10-13 BR BRPI0516152-5A patent/BRPI0516152A/pt active Search and Examination
- 2005-10-13 NZ NZ554265A patent/NZ554265A/en not_active IP Right Cessation
- 2005-10-13 CN CN2012100736124A patent/CN102727462A/zh active Pending
- 2005-10-13 JP JP2007537313A patent/JP4976302B2/ja not_active Expired - Fee Related
- 2005-10-13 MX MX2007004655A patent/MX2007004655A/es active IP Right Grant
- 2005-10-13 CN CNA2005800357056A patent/CN101043873A/zh active Pending
- 2005-10-13 EA EA200700614A patent/EA012371B1/ru not_active IP Right Cessation
- 2005-10-13 US US11/665,665 patent/US20090196920A1/en not_active Abandoned
- 2005-10-13 DK DK05802903.4T patent/DK1803440T3/da active
- 2005-10-13 ZA ZA200703509A patent/ZA200703509B/xx unknown
- 2005-10-13 EP EP05802903A patent/EP1803440B1/en not_active Not-in-force
- 2005-10-13 DE DE602005021668T patent/DE602005021668D1/de active Active
- 2005-10-13 PT PT05802903T patent/PT1803440E/pt unknown
- 2005-10-13 ES ES05802903T patent/ES2347055T3/es active Active
- 2005-10-13 WO PCT/ES2005/000542 patent/WO2006045865A1/es active Application Filing
- 2005-10-13 KR KR1020077008798A patent/KR101413339B1/ko not_active IP Right Cessation
- 2005-10-13 CA CA2583756A patent/CA2583756C/en not_active Expired - Fee Related
-
2007
- 2007-04-11 IL IL182466A patent/IL182466A/en not_active IP Right Cessation
-
2010
- 2010-08-30 CY CY20101100790T patent/CY1110751T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR20070083715A (ko) | 2007-08-24 |
CA2583756C (en) | 2013-12-24 |
IL182466A (en) | 2013-06-27 |
PL1803440T3 (pl) | 2010-12-31 |
JP2008517040A (ja) | 2008-05-22 |
CN102727462A (zh) | 2012-10-17 |
DK1803440T3 (da) | 2010-10-04 |
NZ554265A (en) | 2010-12-24 |
PT1803440E (pt) | 2010-08-31 |
AU2005298587B2 (en) | 2010-08-05 |
ES2255426B1 (es) | 2007-08-16 |
EA012371B1 (ru) | 2009-10-30 |
IL182466A0 (en) | 2007-07-24 |
ZA200703509B (en) | 2008-09-25 |
SI1803440T1 (sl) | 2010-10-29 |
MX2007004655A (es) | 2008-03-10 |
DE602005021668D1 (de) | 2010-07-15 |
EP1803440A1 (en) | 2007-07-04 |
JP4976302B2 (ja) | 2012-07-18 |
WO2006045865A1 (es) | 2006-05-04 |
EA200700614A1 (ru) | 2007-10-26 |
CA2583756A1 (en) | 2006-05-04 |
CN101043873A (zh) | 2007-09-26 |
ATE469641T1 (de) | 2010-06-15 |
EP1803440B1 (en) | 2010-06-02 |
US20090196920A1 (en) | 2009-08-06 |
AU2005298587A1 (en) | 2006-05-04 |
KR101413339B1 (ko) | 2014-06-27 |
ES2255426A1 (es) | 2006-06-16 |
CY1110751T1 (el) | 2015-06-10 |
ES2347055T3 (es) | 2010-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516152A (pt) | formulação farmacêutica que compreende microcápsulas de estatinas ressuspensas em éster alquìlicos de ácidos graxos poli-insaturados (pufa) | |
WO2004043894A8 (en) | Lipase-catalysed esterification of marine oil | |
BR0209749A (pt) | Coenzima q e epa ou outro ácido graxo essencial | |
DK1419768T3 (da) | Præparater med virkning til forebyggelse eller bedring af tilstande eller sygdomme forårsaget af hjernehypofunktion | |
HK1103069A1 (en) | Method of making alkyl esters using glycerin | |
NO990739L (no) | Lipase-katalysert esterifikasjon av marine oljer | |
BRPI0416403A (pt) | composição de óleo enriquecida em diglicerìdeo com ácido linoléico conjugado | |
CO5700724A2 (es) | Metodos y composiciones farmaceuticas para la obtencion confiable de niveles aceptables de testosterona en suero | |
BRPI0517095A (pt) | processos para preparação de composições de óleo | |
BRPI0418921A (pt) | uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição | |
IL180602A0 (en) | Composition containing statins and omega-3 fatty acids | |
BRPI0515958A (pt) | composição agroquìmica contendo éster de ácido fosfórico | |
AU2002314131A1 (en) | Method and device for obtaining fatty acid esters from native oils and fats by means of the enzymatic separation thereof | |
BRPI0500333A (pt) | processo catalìtico para esterificação de ácidos graxos | |
MX2009004339A (es) | Alcoholes de acido graso. | |
AR090072A1 (es) | Aceite que comprende acidos grasos poliinsaturados estables a la oxidacion | |
TR199801519T2 (xx) | Yenebilir bitkisel ya� bile�imi. | |
EA201200935A1 (ru) | Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний | |
ATE388933T1 (de) | Um- und veresterung von fetts uren und triglyceriden durch dispergieren und dispersionsverfahren zur herstellung von fettsäuremethylestern | |
BR0109586A (pt) | Composições contendo policarbonato | |
FR2735784B1 (fr) | Composition de fluide hydraulique comportant un systeme inhibiteur de corrosion | |
AR048014A1 (es) | Aceite de girasol con distribucion modificada de acidos grasos en la molecula de triacilglicerol | |
AR053005A1 (es) | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa) | |
WO2002092779A3 (en) | Method for enriching tissues in long chain polyunsaturated fatty acids | |
TW200600583A (en) | Method for kinetic resolution of α-substituted acids and esters thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: GP PHARM S.A. (ES) , DEFIANTE FARMACEUTICA, S.A. ( Free format text: ALTERADO DE: DEFIANTE FARMACEUTICA LDA. |
|
B25A | Requested transfer of rights approved |
Owner name: GP PHARM S.A. (ES) , SIGMA -TAU INDUSTRIE FARMACEU |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |